What Researchers Did
Researchers investigated the therapeutic potential of normobaric and hyperbaric oxygen during and after transient middle cerebral artery occlusion (MCAO) in rodents, and identified oxygen-sensitive gene expression.
What They Found
Supplemental oxygen administered during acute ischemic stroke significantly attenuated percent stroke hemisphere lesion volume (room air=22.4+/-1.8, iNBO=9.9+/-3.6, iHBO=6.6+/-4.8). However, identical treatment immediately after reperfusion exacerbated lesion volume (rNBO=29.8+/-3.6, rHBO=35.4+/-7.6). Unbiased screening identified 5,769 differentially expressed genes, and supplemental oxygen limited leukocyte accumulation by attenuating proinflammatory chemokine response.
What This Means for Canadian Patients
This research suggests that the timing of oxygen therapy is crucial for stroke patients, with early administration potentially beneficial and post-reperfusion administration potentially harmful. Future clinical trials are needed to determine if these findings translate to improved outcomes for Canadian patients experiencing acute ischemic stroke.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada or by Canadian researchers.
Study Limitations
The study was conducted in rodents, meaning the findings may not directly translate to human physiology and clinical outcomes.